Sudair Pharma manufactures and distributes pharmaceutical products, focusing on oncology treatments and a diversified portfolio for various tumor types.  The self-described company also emphasizes pharmacovigilance and drug safety.

Sudair Pharma

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

George Rathmann

Amgen Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Metric
Company Name	Sudair Pharma	Amgen Inc.	Pfizer Inc.
Symbol		AMGN	PFE
MSH ID	COM:SUDAIRPHARMA	COM:AMGEN	COM:PFIZER
Market	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare
Industry	Pharmaceutical Manufacturing	Drug Manufacturers - General	Drug Manufacturers - General
Country	SA	US	US
Stage
Employee Count		26.70K	88K
Website	sudairpharma.com	amgen.com	pfizer.com
LinkedIn		amgen	pfizer
Founders

Metric
Market Cap	172.56B	160.65B
Enterprise Value
Monthly Web Traffic	1.00M	1.84M
Web Traffic Growth	-0.02	0.15
Valuation
Raised Capital	28.50B	1B

Metric
Revenue	28.19B	58.50B
Revenue (LTM)
Revenue (NTM)
Gross Profit	19.74B	29.28B
EBITDA	7.90B	10.53B
Operating Income	7.90B	4.24B
Net Income	6.72B	2.12B
EPS	12.56	0.38
Diluted EPS	12.49	0.38
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.70	0.52
Operating Profit Margin	0.32	0.06
EBITDA Margin	0.28	0.18
Net Profit Margin	0.24	0.04
Return on Equity	1.03	0.02
Return on Assets	0.07	0.01
Return on Capital Employed	0.12	5.56

COM:SUDAIRPHARMA

Sudair Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	22.81	14.35
P/B Ratio	22.55	1.55
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.11	3.21
EV Multiple	12.57	17.74

Metric
Days Sales Outstanding	83.59	79.90
Days Payables Outstanding	69.95	72.06
Days Inventory Outstanding	411.08	155.46
Operating Cycle	513.92	230.19
Cash Conversion Cycle	445.24	160.85
Asset Turnover	0.34	141.27

Metric
Operating Cash Flow	8.47B	8.70B
Free Cash Flow	7.36B	4.79B
Cash Flow to Debt	0.13	0.12
Operating Cash Flow/Sales	0.30	0.16
Free Cash Flow Yield	0.06	0.05

Metric
Cash & Equivalents	10.94B	2.85B
Accounts Receivable	-1.01B	347M
Inventory	9.52B	10.19B
Goodwill	18.63B	67.78B
Debt to Capitalization	0.93	0.45
Debt to Assets	0.67	0.30
Current Ratio	2.86	2.38
Quick Ratio	1.62	94.70

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.03	0.01
R&D to Revenue	0.17	0.17
SG&A to Revenue